Long-term secukinumab study for children with arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at how well secukinumab (Cosentyx) works over time for children with certain types of juvenile arthritis. It aims to understand the best treatment strategies and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- You have been diagnosed with enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (JPsA).
- You have already started taking secukinumab after it was approved in Germany.
- Your parent or guardian has signed a consent form, and you (if 11-17) have agreed to join.
- You are not taking other biologic drugs or JAK inhibitors along with secukinumab.
- You are not in any other research study testing a new treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This trial lets people who already did a previous secukinumab (an injection for certain inflammatory conditions) study continue treatment afterward. It’s mainly for people who are still getting benefit and can’t otherwise get the approved medication through their local system.
This trial is testing the safety of a medicine called secukinumab in adults with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine). It may be a good option if you have this condition and want to help researchers learn more about how safe this treatment is for Indian patients.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
Hear when a new Enthesitis-related Arthritis (ERA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.